Sabra Healthcare REIT, Inc. (NASDAQ:SBRA) Given Consensus Recommendation of "Moderate Buy" by Brokerages

Key Points

• Sabra Healthcare REIT received a consensus recommendation of Moderate Buy from 10 analysts (five hold, four buy, one strong buy) with an average 12‑month price target of $22.00, and several firms recently raised targets to $21–$22 while Weiss Ratings upgraded to buy (a-).
• In the most recent quarter Sabra reported EPS of $0.11, missing the $0.37 consensus by $0.26, with revenue of $201.35 million (up 16.2% YoY); management set FY2026 guidance of $1.550–$1.590 EPS versus analysts' ~1.51 estimate.
• The company pays a quarterly dividend of $0.30 (annualized $1.20) for a yield of 5.9%, with a reported payout ratio of 187.5%.

Shares of Sabra Healthcare REIT, Inc. (NASDAQ:SBRA - Get Free Report) have received a consensus recommendation of "Moderate Buy" from the ten research firms that are covering the company, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company. The average twelve-month price objective among analysts that have issued ratings on the stock in the last year is $22.00.

A number of research firms recently weighed in on SBRA. Cantor Fitzgerald lifted their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Tuesday, February 17th. Wells Fargo & Company lifted their price target on Sabra Healthcare REIT from $21.00 to $22.00 and gave the company an "overweight" rating in a research note on Thursday, March 26th. Truist Financial lifted their price target on Sabra Healthcare REIT from $21.00 to $22.00 and gave the company a "hold" rating in a research note on Friday, March 13th. UBS Group lifted their price target on Sabra Healthcare REIT from $20.00 to $21.00 and gave the company a "neutral" rating in a research note on Thursday, February 19th. Finally, Weiss Ratings upgraded Sabra Healthcare REIT from a "buy (b+)" rating to a "buy (a-)" rating in a research note on Wednesday, March 18th.

Sabra Healthcare REIT Trading Up 0.9%

NASDAQ:SBRA opened at $20.28 on Tuesday. The firm has a market cap of $5.11 billion, a P/E ratio of 31.69, a PEG ratio of 1.60 and a beta of 0.67. The company has a current ratio of 4.29, a quick ratio of 4.29 and a debt-to-equity ratio of 0.90. The stock's 50 day simple moving average is $20.21 and its 200-day simple moving average is $19.30. Sabra Healthcare REIT has a 12-month low of $17.04 and a 12-month high of $21.07.

Sabra Healthcare REIT (NASDAQ:SBRA - Get Free Report) last posted its quarterly earnings results on Thursday, February 12th. The real estate investment trust reported $0.11 earnings per share for the quarter, missing analysts' consensus estimates of $0.37 by ($0.26). Sabra Healthcare REIT had a net margin of 20.09% and a return on equity of 5.63%. The business had revenue of $201.35 million during the quarter, compared to analysts' expectations of $201.97 million. During the same quarter last year, the firm earned $0.36 earnings per share. The firm's quarterly revenue was up 16.2% compared to the same quarter last year. Sabra Healthcare REIT has set its FY 2026 guidance at 1.550-1.590 EPS. Equities analysts anticipate that Sabra Healthcare REIT will post 1.51 EPS for the current year.

Sabra Healthcare REIT Announces Dividend

The company also recently announced a quarterly dividend, which was paid on Friday, February 27th. Shareholders of record on Friday, February 13th were given a dividend of $0.30 per share. This represents a $1.20 dividend on an annualized basis and a yield of 5.9%. The ex-dividend date was Friday, February 13th. Sabra Healthcare REIT's payout ratio is presently 187.50%.

Institutional Trading of Sabra Healthcare REIT

Institutional investors have recently bought and sold shares of the company. Rothschild Investment LLC boosted its position in Sabra Healthcare REIT by 164.6% during the fourth quarter. Rothschild Investment LLC now owns 1,429 shares of the real estate investment trust's stock worth $27,000 after purchasing an additional 889 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in Sabra Healthcare REIT by 97.7% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the real estate investment trust's stock worth $27,000 after purchasing an additional 714 shares in the last quarter. Founders Capital Management purchased a new stake in Sabra Healthcare REIT during the third quarter worth $28,000. Strengthening Families & Communities LLC purchased a new stake in Sabra Healthcare REIT during the fourth quarter worth $29,000. Finally, Danske Bank A S purchased a new stake in Sabra Healthcare REIT during the third quarter worth $30,000. 99.40% of the stock is currently owned by hedge funds and other institutional investors.

About Sabra Healthcare REIT

Sabra Healthcare REIT, Inc NASDAQ: SBRA is a real estate investment trust that acquires, owns and operates net‐lease healthcare properties. Its diversified portfolio spans senior housing communities, skilled nursing and rehabilitation centers, outpatient medical facilities, medical office buildings, hospitals and life science properties. Sabra structures long‐term, triple‐net lease agreements with healthcare operators, providing stable rental income streams while allowing tenants to focus on patient care and operational excellence.

Serving a broad spectrum of care segments, Sabra's tenants include both regional and national providers of assisted living, independent living, memory care, post‐acute rehabilitation and research and development laboratories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.